8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Feb 26, 2026·SEC
Janux Therapeutics, Inc.(JANX)Earnings, Financials & Key Ratios
JANX•NASDAQ
$15.41
Price updated Jul 6, 2026
AboutJanux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.Show more
- Revenue$10M-5.6%
- EBITDA-$156M-60.8%
- Net Income-$114M-64.7%
- EPS (Diluted)-1.83-43.0%
- Gross Margin79.71%-1.0%
- EBITDA Margin-1556.38%-70.3%
- Operating Margin-1576.67%-68.9%
- Net Margin-1136.25%-74.4%
- ROE-11.48%-13.7%
JANX Price & Volume
Janux Therapeutics, Inc. (JANX) stock price & volume — 10-year historical chart
Loading chart...
Clinical R&D Intensity Outpaces Milestone Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- Janux Therapeutics faces a precarious financial outlook as its aggressive R&D investment, which peaked at $34.7M in 2025Q2, continues to outstrip its episodic and volatile milestone-driven revenue.
- The company's reliance on non-recurring collaboration payments creates significant uncertainty, as evidenced by the recent emergence of $46.3M in deferred revenue that may delay immediate liquidity.
- Investors should remain cautious regarding the rapid depletion of cash reserves, which fell from $430.6M in 2024Q4 to $51.8M by 2026Q1, as the firm navigates high-stakes clinical development cycles.
Verdict Logic
the rapid contraction of cash reserves from $430.6M to $51.8M over five quarters suggests an unsustainable burn rate that necessitates further capital raises to support ongoing clinical operations.
JANX Growth Metrics
Janux Therapeutics, Inc. (JANX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years5.11%
TTM131.5%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-47.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-35.29%
Return on Capital
10 Years-32.11%
5 Years-17.22%
3 Years-16.66%
Last Year-15.56%
JANX Recent Earnings
Janux Therapeutics, Inc. (JANX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 6/12 qtrs (75%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.39+25.0%
$0.52
Rev
$4M-14.3%
$4M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.51+21.5%
$0.65
Rev
$8M+9356.0%
$83,333
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.39+35.0%
$0.60
Rev
$10M
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.55-14.6%
$0.48
Rev
—
$300,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.39vs $0.52+25.0% | $4Mvs $4M-14.3% |
| Q1 2026 | Feb 26, 2026 | $0.51vs $0.65+21.5% | $8Mvs $83,333+9356.0% |
| Q4 2025 | Nov 6, 2025 | $0.39vs $0.60+35.0% | $10M |
| Q3 2025 | Aug 7, 2025 | $0.55vs $0.48-14.6% | —vs $300,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Janux Therapeutics, Inc. (JANX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.41 | $939.77M | -8.42 | -5.55% | -1136.25% | -11.48% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $29.94 | $3.48B | -34.41 | 48.29% | -188.15% | -41.54% | — | |
| $189.99 | $40.39B | -31.93 | — | — | -83.22% | — |
Compare JANX vs Peers
Janux Therapeutics, Inc. (JANX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
JANX SEC Filings & Documents
Janux Therapeutics, Inc. (JANX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when JANX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
JANX Frequently Asked Questions
Janux Therapeutics, Inc. (JANX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Janux Therapeutics, Inc.'s revenue?
Janux Therapeutics, Inc. (JANX) reported $21.6M in revenue for fiscal year 2025.
How fast is Janux Therapeutics, Inc. growing?
Janux Therapeutics, Inc. (JANX) saw revenue decline by 5.6% over the past year.
Is JANX profitable?
Janux Therapeutics, Inc. (JANX) reported a net loss of $114.5M for fiscal year 2025.
Dividend & Returns
What is JANX's return on equity?
Janux Therapeutics, Inc. (JANX) has a return on equity (ROE) of -11.5%. Negative ROE indicates the company is unprofitable.
What is Janux Therapeutics, Inc.'s free cash flow?
Janux Therapeutics, Inc. (JANX) had negative free cash flow of $78.5M in fiscal year 2025, likely due to heavy capital investments.